Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Congress Park Capital LLC

by · The Cerbat Gem

Congress Park Capital LLC raised its position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report) by 25.3% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,978,078 shares of the biotechnology company’s stock after purchasing an additional 399,577 shares during the quarter. Heron Therapeutics comprises 1.5% of Congress Park Capital LLC’s portfolio, making the stock its 21st largest holding. Congress Park Capital LLC owned about 1.31% of Heron Therapeutics worth $3,936,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Orchard Capital Management LLC boosted its stake in shares of Heron Therapeutics by 4.7% during the 4th quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company’s stock worth $3,814,000 after acquiring an additional 100,603 shares in the last quarter. Diversified Trust Co purchased a new stake in shares of Heron Therapeutics in the first quarter valued at $66,000. Commonwealth Equity Services LLC lifted its holdings in shares of Heron Therapeutics by 3.1% in the first quarter. Commonwealth Equity Services LLC now owns 338,526 shares of the biotechnology company’s stock valued at $938,000 after purchasing an additional 10,122 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Heron Therapeutics in the first quarter valued at $90,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Heron Therapeutics by 80.7% in the first quarter. BNP Paribas Financial Markets now owns 51,296 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 22,904 shares in the last quarter. 80.01% of the stock is owned by institutional investors.

Heron Therapeutics Trading Down 0.5 %

Shares of NASDAQ:HRTX traded down $0.01 during midday trading on Friday, hitting $1.81. The company’s stock had a trading volume of 1,740,186 shares, compared to its average volume of 2,489,884. The stock’s 50 day simple moving average is $1.98 and its 200 day simple moving average is $2.69. Heron Therapeutics, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $3.93.

Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.02). The firm had revenue of $36.02 million during the quarter, compared to the consensus estimate of $35.35 million. During the same quarter in the prior year, the company posted ($0.35) earnings per share. Equities research analysts predict that Heron Therapeutics, Inc. will post -0.1 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on HRTX. Needham & Company LLC restated a “buy” rating and issued a $5.00 target price on shares of Heron Therapeutics in a report on Wednesday, September 25th. Rodman & Renshaw began coverage on Heron Therapeutics in a report on Thursday, June 13th. They issued a “buy” rating and a $7.00 target price for the company.

View Our Latest Research Report on HRTX

About Heron Therapeutics

(Free Report)

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

See Also

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX – Free Report).